profit from every $100 of sales.
$0$100
Indivior Pharmaceuticals
$36.28+2.57% today
+23.5% in 1 year
1-year low $28.781-year high $41.83
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $20.39 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Indivior Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $901 million in 2022 to $1.24 billion in 2025, with $210 million of profit last year.
SalesProfit
Indivior Pharmaceuticals vs. similar companies
Indivior Pharmaceuticals grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Indivior Pharmaceuticals | 20.4× · Fair price | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Indivior Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 901 | 1,093 | 1,188 | 1,239 | |
| 750 | 919 | 957 | 993 | |
| 215 | 247 | 234 | 265 | |
| -46 | -95 | 89 | 304 | |
| -44 | -126 | 7 | 210 | |
| -0.38 | 0.01 | -0.36 | 1.64 | |
| 83.2% | 84.1% | 80.6% | 80.1% | |
| 23.9% | 22.6% | 19.7% | 21.4% | |
| -4.9% | -11.5% | 0.6% | 16.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,769 | 1,760 | 1,316 | 1,201 |
| Cash | 774 | 316 | 319 | 195 |
| Total debt | 277 | 283 | 375 | 351 |
| Total liabilities | 1,718 | 1,952 | 1,653 | 1,300 |
| 51 | -192 | -337 | -99 | |
| 146 | 142 | 132 | 128 | |
| -14.9% | -95.5% | 126.8% | 89.0% | |
| -86.3% | 65.6% | -2.1% | -212.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -300 | 36 | -27 | |
| 5 | 53 | 31 | 67 | |
| -9 | -353 | 5 | -94 | |
| Dividends paid | – | – | – | – |
| 90 | 33 | 173 | 11 | |
| 16 | 21 | 24 | 26 |
Valuation
- 20.4×
- 10.7×
- –
- -33.1×
- 3.5×
- –
- 14.6×
- -2.2%
- 4.9%
- 0.0%
Profitability
- 80.1%
- 21.4%
- 16.9%
- 35.0%
- 85.7%
- -4.3%
- -142.0%
- 21.0%
- 102.9%
- 5.7%
Growth
- +11.2%
- –
- −1,428.6%
- –
- −3.8%
Financial health
- 0.7×
- -3.53
- 42.5%
- 10.8×
- 0.86
- 0.66
- 1.08
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 958
Top 20%of 889
Top 36%of 601
Top 49%of 890
Bottom 28%of 987
What analysts expect
- Average price target
- $44.67
- Range
- $36.00 – $50.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 0.96 | 0.64 | +50.0% |
| Feb 26, 2026 | 0.82 | 0.65 | +26.2% |
| Oct 30, 2025 | 0.72 | 0.38 | +89.5% |
| Jul 31, 2025 | 0.51 | 0.26 | +96.2% |
| Apr 24, 2025 | 0.41 | 0.22 | +86.4% |
| Feb 20, 2025 | 0.32 | 0.32 | +0.0% |
| Oct 24, 2024 | 0.54 | 0.31 | +74.2% |
| Jul 25, 2024 | 0.44 | 0.40 | +10.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/7Passes 4 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
36No pass
Philip Fisher
63Pass
Peter Lynch
66Pass
Joel Greenblatt
74Pass
Charlie Munger
62Pass
Terry Smith
53No pass
Questions about Indivior Pharmaceuticals
Is Indivior Pharmaceuticals a good stock to buy?
A solid business at a fair price. 4 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Indivior Pharmaceuticals AI analysis
What does Indivior Pharmaceuticals do?
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It is in Drug Manufacturers - Specialty & Generic, based in North Chesterfield, VA, United States, with 827 employees.
Does Indivior Pharmaceuticals pay a dividend?
No. Indivior Pharmaceuticals does not pay a dividend at the moment; in 2025 it returned $11.0 million to shareholders by buying back its own shares.
Is Indivior Pharmaceuticals stock halal?
Yes. Indivior Pharmaceuticals passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has Indivior Pharmaceuticals stock done over the past year?
Up 23.5% over the past twelve months, to $36.28. It traded between $28.78 and $41.83 and is 13.3% below its high.
Who are Indivior Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Indivior Pharmaceuticals's.
Prices: daily closes to Nov 2, 2026. Fundamentals: company reports via invest-like data.